Platelet activating factors are associated with depressive symptoms in coronary artery disease patients: A hypothesis-generating study

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 2309-2314

  Mazereeuw, Graham ^a,b,d   Herrmann, Nathan ^a,b   Xu, Hongbin ^c,d   Blanchard, Alexandre P ^c,d   Figeys, Daniel ^c,d   Oh, Paul I ^e   Bennett, Steffany A L ^c,d   Lanctôt, Krista L ^a,b,d,e  

^a Canada   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e TORONTO REHABILITATION INSTITUTE   (Canada)

Author keywords

Biomarker; Cardiovascular; Depression; Inflammation; Lipidomics; Oxidative stress; Vascular depression

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPIDOME; THROMBOCYTE ACTIVATING FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DSM-IV; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HAMILTON DEPRESSION RATING SCALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPID BLOOD LEVEL; MALE; PSYCHOLOGIC ASSESSMENT; THROMBOCYTE ACTIVATION;

EID: 84941242012     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S87111     Document Type: Article

References (36)

1. Celano CM, Huffman JC. Depression and cardiac disease: a review. Cardiol Rev. 2011;19:130-142.
2. Lesperance F, Frasure-Smith N. Depression in patients with cardiac disease: a practical review. J Psychosom Res. 2000;48:379-391.
3. Dowlati Y, Herrmann N, Swardfager WL, Reim EK, Lanctot KL. Efficacy and tolerability of antidepressants for treatment of depression in coronary artery disease: a meta-analysis. Can J Psychiatry. 2010;55:91-99.
4. Blumenthal JA, Sherwood A, Babyak MA, et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. J Am Coll Cardiol. 2012;16:1053-1063.
5. Stapelberg NJC, Neumann DL, Shum DHK, McConnell H, Hamilton-Craig I. A topographical map of the causal network of mechanisms underlying the relationship between major depressive disorder and coronary heart disease. Aust NZ J Psychiatry. 2011;45:351-369.
6. Baune BT, Stuart M, Gilmour A, et al. The relationship between subtypes of depression and cardiovascular disease: a systematic review of biological models. Transl Psychiatry. 2012;13:e92.
7. Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry. 2013;18(5):595-606.
8. Kuebler WM, Yang Y, Samapati R, Uhlig S. Vascular barrier regulation by PAF, ceramide, caveolae, and NO - an intricate signaling network with discrepant effects in the pulmonary and systemic vasculature. Cell Physiol Biochem. 2010;26:29-40.
9. Arai A, Lynch G. Antagonists of the platelet-activating factor receptor block long-term potentiation in hippocampal slices. Eur J Neurosci. 1992; 4:411-419.
10. Chen H, Zheng P, Zhu H, et al. Platelet-activating factor levels of serum and gingival crevicular fluid in nonsmoking patients with periodontitis and/or coronary heart disease. Clin Oral Investig. 2010;14:629-636.
11. Winkler K, Winkelmann BR, Scharnagl H, et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation. 2005;111:980-987. [Erratum in Circulation. 2005;111(24):e444].
12. Samsamshariat S, Basati G, Movahedian A, Pourfarzam M, Sarrafzadegan N. Elevated plasma platelet-activating factor acetylhydrolase activity and its relationship to the presence of coronary artery disease. J Res Med Sci. 2011;16:674-679.
13. Wilensky RL, Macphee CH. Lipoprotein-associated phospholipase A(2) and atherosclerosis. Curr Opin Lipidol. 2009;20:415-420.
14. Winkler K, Hoffmann MM, Winkelmann BR, et al. Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardiovascular health study). Clin Chem. 2007;53:1440-1447.
15. Klabunde RE, Anderson DE. Role of nitric oxide and reactive oxygen species in platelet-activating factor-induced microvascular leakage. J Vasc Res. 2002;39:238-245.
16. Farooqui AA, Horrocks LA, Farooqui T. Modulation of inflammation in brain: a matter of fat. J Neurochem. 2007;101:577-599.
17. Mazereeuw G, Herrmann N, Bennett SAL, et al. Platelet activating factors in depression and coronary artery disease: A potential biomarker related to inflammatory mechanisms and neurodegeneration. Neurosci Biobehav Rev. 2013;37:1611-1621.
18. Molloy DW. Standardized Mini Mental State Examination. Troy, ON, Canada: New Grange Press; 1999.
19. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
20. Strik JJ, Honig A, Lousberg R, Denollet J. Sensitivity and specificity of observer and self-report questionnaires in major and minor depression following myocardial infarction. Psychosomatics. 2001;42:423-428.
21. First MB, Spitzer RL, Gibbon M, et al. Structured clinical interview for DSM-IV diagnoses (SCID): Clinician and research versions. New York, NY: Biometrics Research Department, Columbia University; 1996.
22. Mazereeuw G, Herrmann N, Xu H, et al. Platelet-activating factors are associated with cognitive deficits in depressed coronary artery disease patients: a hypothesis-generating study. J Neuroinflammation. 2014; 11:119.
23. Whitehead SN, Hou W, Ethier M, et al. Identification and quantitation of changes in the platelet activating factor family of glycerophospholipids over the course of neuronal differentiation by high-performance liquid chromatography electrospray ionization tandem mass spectrometry. Anal Chem. 2007;79:8539-8548.
24. Ryan SD, Whitehead SN, Swayne LA, et al. Amyloid-β42 signals tau hyperphosphorylation and compromises neuronal viability by disrupting alkylacylglycerophosphocholine metabolism. Proc Natl Acad Sci U S A. 2009;106:20936-20941.
25. Blanchard AP, McDowell GSV, Valenzuela N, et al. Visualization and Phospholipid Identification (VaLID): online integrated search engine capable of identifying and visualizing glycerophospholipids with given mass. Bioinformatics. 2013;29:284-285.
26. Dowlati Y, Herrmann N, Swardfager W, et al. Relationship between hair cortisol concentrations and depressive symptoms in patients with coronary artery disease. Neuropsychiatr Dis Treat. 2010;7:393-400.
27. Todaro JF, Shen B-J, Niaura R, Tilkemeier PL. Prevalence of depressive disorders in men and women enrolled in cardiac rehabilitation. J Cardiopulm Rehabil. 2005;25:71-75; quiz 76-77.
28. Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol. 2004;44:1945-1956.
29. Demirkan A, Isaacs A, Ugocsai P, et al. Plasma phosphatidylcholine and sphingomyelin concentrations are associated with depression and anxiety symptoms in a Dutch family-based lipidomics study. J Psychiatr Res. 2013;47:357-362.
30. Faria R, Santana MM, Aveleira CA, et al. Alterations in phospholipidomic profile in the brain of mouse model of depression induced by chronic unpredictable stress. Neuroscience. 2014;273:1-11.
31. Ryan SD, Harris CS, Carswell CL, Baenziger JE, Bennett SAL. Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons. J Lipid Res. 2008;49:2250-2258.
32. Groenewold NA, Doornbos B, Zuidersma M, et al. Comparing cognitive and somatic symptoms of depression in myocardial infarction patients and depressed patients in primary and mental health care. PLoS One. 2013;8:e53859.
33. Ketterer MW, Mahr G, Goldberg AD. Psychological factors affecting a medical condition: ischemic coronary heart disease. J Psychosom Res. 2000;48:357-367.
34. Sato S, Yeh TL. Challenges in treating patients with major depressive disorder: the impact of biological and social factors. CNS Drugs. 2013;27(Suppl 1):S5-S10.
35. Maes M, Ruckoanich P, Chang YS, Mahanonda N, Berk M. Multiple aberrations in shared inflammatory and oxidative & nitrosative stress (IO&NS) pathways explain the co-association of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients. Prog Neuro-Psychopharmacol Biol Psychiatry. 2011;35:769-783.
36. Fahy E, Cotter D, Sud M, Subramaniam S. Lipid classification, structures and tools. Biochim Biophys Acta. 2011;1811:637-647.